Successful infliximab treatment in siblings with Netherton syndrome: Unveiling a novel SPINK5 gene variant and literature review

Australas J Dermatol. 2024 May;65(3):e45-e49. doi: 10.1111/ajd.14234. Epub 2024 Feb 28.

Abstract

Netherton syndrome (NS) is a rare autosomal recessive genodermatosis. In this article, we present two siblings with NS who harbour a novel variant in the SPINK5 gene and were treated with infliximab infusions. Both patients exhibited the characteristic clinical triad of NS, and their whole exome sequencing analysis revealed a homozygous variant, c.1820+53G>A, in the SPINK5 gene. Notably, this is the first documented instance of homozygosity for this particular variant. Despite the absence of a specific treatment, both patients achieved total clearance of the skin lesions, and a significant decrease in total IgE levels was documented.

Keywords: Netherton syndrome; eczema; genetic skin diseases; immunoglobulin E; infliximab.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Dermatologic Agents / therapeutic use
  • Female
  • Homozygote
  • Humans
  • Infliximab* / therapeutic use
  • Male
  • Netherton Syndrome* / drug therapy
  • Netherton Syndrome* / genetics
  • Serine Peptidase Inhibitor Kazal-Type 5* / genetics
  • Siblings

Substances

  • SPINK5 protein, human